BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Hyundai Bioscience Launches Clinical Trials for Innovative Niclosamide-Based Cancer Drug

Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative...

April 23, 2024 | News

Hyundai Bioscience to Conduct Global Clinical Trials for Groundbreaking Dengue Treatment

Hyundai Bioscience CEO Oh Sang-gi, announced its plan to launch global clinical trials for a revolutionary treatment targeting all four serotypes of ...

April 22, 2024 | News

X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)

"This submission was the culmination of several years of development activities and the establishment of a Good Manufacturing Practices (GMP) manufacturing...

April 19, 2024 | News

Sartorius and TheWell Bioscience Partner to Enable More Accurate Predictions in Drug Discovery

Solutions address shift from animal-based to more human-relevant organoid models, resulting in more accurate predictions in drug discovery Synergies wit...

April 10, 2024 | News

RemeGen's Telitacicept Secures FDA Fast Track Status for Primary Sjögren's Syndrome Treatment

RemeGen , a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) rec...

April 03, 2024 | News

Innovent and HUTCHMED's Endometrial Cancer Therapy Receives Priority Review by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

April 03, 2024 | News

Alebund Pharmaceuticals Receives FDA Orphan Drug Designation for AP303 in ADPKD Treatment

Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for th...

April 01, 2024 | News

Hoth Therapeutics' Merveille.ai Achieves Breakthrough in Obesity Treatment with AI-Driven Therapeutic Candidate

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its sub...

March 28, 2024 | News

TiumBio Initiates Phase 1b Trial for New Hemophilia Treatment TU7710

TiumBio Co., Ltd., a trailblazer in the biopharmaceutical landscape, dedicated to crafting groundbreaking therapies for rare and untreatabl...

March 27, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

March 26, 2024 | News

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is plea...

March 25, 2024 | News

AriBio Secures Exclusive $770M Deal for Alzheimer's Drug in China

AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in Chin...

March 25, 2024 | News

Vertex Pharmaceuticals Receives FDA Clearance for Innovative ADPKD Drug Trial

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) f...

March 22, 2024 | News

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immun...

March 22, 2024 | News

Stay Connected